About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNCT05392387

Treatment and Prognosis of Patients With Chronic HBV Infection

Hepatitis B virus (HBV) infection is a major global health issue with 257 million chronically infected individuals. Of note, China has the largest population accounting for one third of the world's in...

Lead sponsor: Xiangya Hospital of Central South University•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Yan Huang

CONTACT

+86 13874854142 ganrankedrhyan@163.com

Sponsors

Lead Sponsor

Xiangya Hospital of Central South University

Patients with chronic HBV infection were recruited in the current study and divided in to peg-IFN-alpha alone group, NAs alone group and the combination therapy group. The serum HBV DNA level, HBV serological test and biochemical examination including serum transaminase level and AFP were recorded every three or six months. The serum, feces, urine and liver (if necessary) samples were collected during follow-up. And the clinical outcomes of patients were evaluated. The clinical and biological features of patients with different clinical outcomes will be compared to explore the factors affecting the antiviral therapeutic efficacy.

Age

18 - 79 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•patients with evidence of chronic HBV infection

Exclusion Criteria

•chronic liver injury mainly caused by other reasons, such as autoimmune diseases, alcohol, drugs and so on.

Related studies

RECRUITINGPhase 1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection

NCT07024641 · Hepatitis B Virus Infection

Active Not RecruitingPhase 2

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

NCT06537414 · Chronic Hepatitis B Virus Infection, Hepatitis B

Active Not RecruitingPhase 2

Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)

NCT06491563 · For Treatment of Chronic Hepatitis B Virus Infection

COMPLETEDPhase 1

A Clinical Study of HH-006 in Untreated Chronic Hepatitis B Virus Infected Patients

NCT07515209 · Chronic Hepatitis B Virus Infection

TERMINATEDPhase 1

A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection

NCT06159062 · Chronic Hepatitis B Virus Infection

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 26, 2022Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment500

Start dateOct 2021

Last updatedMay 26, 2022

Condition

Hepatitis B Virus Infection

Locations shown

Department of Infectious Disease, Xiangya Hospital, Central South University

Changsha, Hunan

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 26, 2022Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions